Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod
- 3 July 2003
- journal article
- research article
- Published by Wiley in International Journal of Dermatology
- Vol. 42 (7) , 576-579
- https://doi.org/10.1046/j.1365-4362.2003.01955.x
Abstract
Background Treatment of cutaneous leishmaniasis can be painful and protracted and cosmetic results are often unsatisfying. The immune modulator imiquimod has been reported to be suitable for the trea...Keywords
This publication has 13 references indexed in Scilit:
- Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis*Parasite Immunology, 2002
- Successful Treatment of Drug‐Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an ImmunomodulatorClinical Infectious Diseases, 2001
- Topical immunomodulators—progress towards treating inflammation, infection, and cancerThe Lancet Infectious Diseases, 2001
- Cutaneous leishmaniasisClinical and Experimental Dermatology, 2000
- Imiquimod: An immune response modifierJournal of the American Academy of Dermatology, 2000
- Immunomodulatory and pharmacologic properties of imiquimodJournal of the American Academy of Dermatology, 2000
- Imiquimod in clinical practiceJournal of the American Academy of Dermatology, 2000
- LeishmaniasisThe Lancet, 1999
- Treatment of Experimental Leishmaniasis with the Immunomodulators Imiquimod and S‐28463: Efficacy and Mode of ActionThe Journal of Infectious Diseases, 1999
- Allopurinol in the Treatment of American Cutaneous LeishmaniasisNew England Journal of Medicine, 1992